CY1116405T1 - Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης - Google Patents

Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης

Info

Publication number
CY1116405T1
CY1116405T1 CY20151100518T CY151100518T CY1116405T1 CY 1116405 T1 CY1116405 T1 CY 1116405T1 CY 20151100518 T CY20151100518 T CY 20151100518T CY 151100518 T CY151100518 T CY 151100518T CY 1116405 T1 CY1116405 T1 CY 1116405T1
Authority
CY
Cyprus
Prior art keywords
formula
coa
acetylo
lactamic
inactions
Prior art date
Application number
CY20151100518T
Other languages
English (en)
Inventor
Scott William Bagley
Robert Lee Dow
David Andrew Griffith
Aaron Christopher Smith
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of CY1116405T1 publication Critical patent/CY1116405T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Η εφεύρεση παρέχει μία ένωση του Τύπου (Ι)˙ ή ένα φαρμακευτικώς αποδεκτό άλας αυτής· όπου G είναι Τύπος (II), Τύπος (III), Τύπος (IV) και Τύπος (V) R1, R2 και R3 είναι όπως περιγράφονται στο παρόν· φαρμακευτικές συνθέσεις αυτής· και τη χρήση αυτής σε αντιμετώπιση νόσων, παθήσεων ή διαταραχών οι οποίες ρυθμίζονται με την αναστολή ενζύμου(ων) ακετυλο-CoA καρβοξυλάσης σε ένα ζώο.
CY20151100518T 2010-10-29 2015-06-12 Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης CY1116405T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40812710P 2010-10-29 2010-10-29
US201161531744P 2011-09-07 2011-09-07
EP11784783.0A EP2632925B1 (en) 2010-10-29 2011-10-18 N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS

Publications (1)

Publication Number Publication Date
CY1116405T1 true CY1116405T1 (el) 2017-02-08

Family

ID=44993633

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100518T CY1116405T1 (el) 2010-10-29 2015-06-12 Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης

Country Status (26)

Country Link
US (3) US8859773B2 (el)
EP (2) EP2632925B1 (el)
JP (2) JP5647356B2 (el)
KR (2) KR20150006899A (el)
CN (2) CN103189377B (el)
AR (1) AR083578A1 (el)
AU (1) AU2011322117B2 (el)
BR (1) BR112013010310A2 (el)
CA (1) CA2815169C (el)
CY (1) CY1116405T1 (el)
DK (1) DK2632925T3 (el)
ES (1) ES2546465T3 (el)
HK (2) HK1186724A1 (el)
HU (1) HUE025078T2 (el)
IL (1) IL225779A0 (el)
MX (1) MX2013004733A (el)
NZ (1) NZ609527A (el)
PL (1) PL2632925T3 (el)
PT (1) PT2632925E (el)
RU (1) RU2540337C2 (el)
SG (1) SG189883A1 (el)
SI (1) SI2632925T1 (el)
TW (3) TWI441823B (el)
UY (1) UY33694A (el)
WO (1) WO2012056372A1 (el)
ZA (1) ZA201303882B (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2632925T1 (sl) * 2010-10-29 2015-07-31 Pfizer Inc. Inhibitorji N1/N2-laktam acetil-CoA karboksilaze
PL2953942T3 (pl) 2013-02-06 2018-03-30 Bayer Cropscience Aktiengesellschaft Podstawione halogenem pochodne pirazolu jako środki do zwalczania szkodników
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN103214327A (zh) * 2013-03-22 2013-07-24 郑州泰基鸿诺药物科技有限公司 一种芳香环或芳杂环三氟甲基酮化合物及其制备方法
CN104230922B (zh) 2013-06-19 2016-12-28 中国科学院上海药物研究所 一类五元杂环并吡啶类化合物及其制备方法和用途
SG11201600711PA (en) 2013-09-12 2016-03-30 Pfizer Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris
KR20160104065A (ko) 2014-01-03 2016-09-02 바이엘 애니멀 헬스 게엠베하 농약으로서의 신규 피라졸릴헤테로아릴아미드
CN104844509A (zh) * 2014-02-14 2015-08-19 河南工业大学 一种条件温和无金属参与的胺基喹啉衍生物的制备方法
KR101731624B1 (ko) * 2014-07-01 2017-05-04 광주과학기술원 세포 리프로그래밍 유도용 조성물
CN106749002A (zh) * 2015-02-12 2017-05-31 佛山市赛维斯医药科技有限公司 一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途
ES2836399T3 (es) 2015-03-10 2021-06-25 Bayer Animal Health Gmbh Derivados de pirazolilo como agentes de control de plagas
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
BR112019017108A2 (pt) 2017-03-16 2020-04-07 Jiangsu Hengrui Medicine Co derivados de heteroaril[4,3-c]pirimidina-5-amina, método de preparação dos mesmos, e usos médicos dos mesmos
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
AU2018236290B2 (en) * 2017-03-16 2022-06-02 Bristol-Myers Squibb Company MK2 inhibitors, synthesis thereof, and intermediates thereto
TW201843139A (zh) 2017-03-30 2018-12-16 瑞士商赫孚孟拉羅股份公司 作為ｈｐｋ１之抑制劑的異喹啉
KR102395451B1 (ko) 2017-11-21 2022-05-09 화이자 인코포레이티드 4-(4-(1-이소프로필-7-옥소-1,4,6,7-테트라히드로스피로[인다졸-5,4'-피페리딘]-1'-카르보닐)-6-메톡시피리딘-2-일)벤조산의 결정질 2-아미노-2-(히드록시메틸)프로판-1,3-디올 염
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
CN109824669A (zh) * 2018-12-21 2019-05-31 西南大学 哌啶螺环酒石酸类化合物制备及应用
WO2021231191A1 (en) * 2020-05-12 2021-11-18 Merck Sharp & Dohme Corp. Factor xi activation inhibitors
CN115666558A (zh) * 2020-05-21 2023-01-31 盐野义制药株式会社 脂肪性肝病的治疗用药物

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002100A (en) 1932-06-27 1935-05-21 Smith Sheffield Shock absorber
JPS4925673B1 (el) * 1970-05-22 1974-07-02
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
EP1383501B1 (en) 2001-02-28 2007-04-04 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2003018586A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease
WO2003072578A1 (en) 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
EA200400980A1 (ru) 2002-02-27 2005-02-24 Пфайзер Продактс Инк. Ингибиторы асс
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004092179A1 (ja) 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
WO2005116014A1 (en) 2004-05-12 2005-12-08 Pfizer Products Inc. Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
US20050267221A1 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
EA010888B1 (ru) 2004-05-25 2008-12-30 Пфайзер Продактс, Инк. Тетраазабензо[е]азуленовые производные и их аналоги
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
CA2614963C (en) 2005-07-19 2014-10-07 Merck & Co., Inc. Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors
US20100160255A1 (en) 2005-07-29 2010-06-24 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
DE602006019304D1 (de) 2005-11-18 2011-02-10 Merck Sharp & Dohme Spirohydantoin-aryl-cgrp-rezeptorantagonisten
US8735595B2 (en) 2006-02-15 2014-05-27 Abbvie Inc. Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
PT2463283E (pt) 2006-04-20 2014-08-27 Pfizer Prod Inc Compostos heterocíclicos de fenil amido condensados para a prevenção e tratamento de doenças mediadas pela glucoquinase
EA200900613A1 (ru) 2006-11-29 2009-10-30 Пфайзер Продактс Инк. Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
EP2123652A1 (en) * 2007-02-20 2009-11-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP2195321B1 (en) 2007-04-12 2016-10-19 Pfizer Inc. 3-amido-pyrrolo[3,4-c]pyrazole-5(1h, 4h,6h) carbaldehyde derivatives as inhibitors of protein kinase c
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
CA2724603A1 (en) * 2008-05-28 2009-12-03 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
US8318762B2 (en) * 2008-05-28 2012-11-27 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
CA2729412A1 (en) 2008-07-04 2010-01-07 Banyu Pharmaceutical Co., Ltd. Novel spirochromanone carboxylic acids
AU2009271634A1 (en) * 2008-07-14 2010-01-21 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
JP2011529483A (ja) 2008-07-29 2011-12-08 ファイザー・インク フッ素化ヘテロアリール
JP4825322B1 (ja) 2008-08-28 2011-11-30 ファイザー・インク ジオキサ−ビシクロ［３．２．１］オクタン−２，３，４−トリオール誘導体
WO2010086820A1 (en) 2009-02-02 2010-08-05 Pfizer Inc. 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
SI2406253T1 (sl) 2009-03-11 2013-09-30 Pfizer Inc. Derivati benzofuranila, uporabljeni kot inhibitorji glukokinaze
CA2754685A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Substituted indazole amides
EP2408780A2 (en) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3.3.1¨nonanes
CA2759843A1 (en) 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
EP2427448A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
NZ596467A (en) 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
JP5114610B1 (ja) * 2009-11-10 2013-01-09 ファイザー・インク Ｎ１−ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害薬
JP2013510191A (ja) * 2009-11-10 2013-03-21 ファイザー・インク Ｎ−２ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害薬
PL2621493T3 (pl) 2010-09-30 2017-01-31 Pfizer Inc. N1-pirazolospiroketonowe inhibitory karboksylazy acetylo-CoA
SI2632925T1 (sl) * 2010-10-29 2015-07-31 Pfizer Inc. Inhibitorji N1/N2-laktam acetil-CoA karboksilaze

Also Published As

Publication number Publication date
US8993586B2 (en) 2015-03-31
CN103189377A (zh) 2013-07-03
KR20150006899A (ko) 2015-01-19
BR112013010310A2 (pt) 2016-11-29
NZ609527A (en) 2014-03-28
SG189883A1 (en) 2013-06-28
PL2632925T3 (pl) 2015-10-30
EP2632925B1 (en) 2015-05-27
CA2815169A1 (en) 2012-05-03
UY33694A (es) 2012-05-31
TWI507406B (zh) 2015-11-11
PT2632925E (pt) 2015-09-01
CN104774205A (zh) 2015-07-15
CN103189377B (zh) 2015-02-25
KR101529404B1 (ko) 2015-06-26
AU2011322117B2 (en) 2015-01-22
SI2632925T1 (sl) 2015-07-31
TW201302751A (zh) 2013-01-16
US20120108619A1 (en) 2012-05-03
HK1209733A1 (en) 2016-04-08
MX2013004733A (es) 2013-07-02
US20150152109A1 (en) 2015-06-04
IL225779A0 (en) 2013-06-27
JP2013542218A (ja) 2013-11-21
US20150025098A1 (en) 2015-01-22
JP5647356B2 (ja) 2014-12-24
WO2012056372A1 (en) 2012-05-03
ES2546465T3 (es) 2015-09-23
TWI441823B (zh) 2014-06-21
US8859773B2 (en) 2014-10-14
ZA201303882B (en) 2014-02-26
HUE025078T2 (en) 2016-01-28
KR20140014078A (ko) 2014-02-05
RU2013116924A (ru) 2014-12-10
EP2632925A1 (en) 2013-09-04
TW201418256A (zh) 2014-05-16
EP2952514A1 (en) 2015-12-09
HK1186724A1 (en) 2014-03-21
AR083578A1 (es) 2013-03-06
JP2015057416A (ja) 2015-03-26
DK2632925T3 (en) 2015-06-29
TW201531472A (zh) 2015-08-16
RU2540337C2 (ru) 2015-02-10
US9181252B2 (en) 2015-11-10
CA2815169C (en) 2015-10-06
AU2011322117A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
CY1116405T1 (el) Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης
CY1118016T1 (el) ΑΝΑΣΤΟΛΕΙΣ Ν1-ΠΥΡΑΖΟΛΟΣΠΕΙΡΟΚΕΤΟΝΗΣ ΑΚΕΤΥΛ-CoA ΚΑΡΒΟΞΥΛΑΣΗΣ
CY1117122T1 (el) Παραγωγα πυραζολοσπειροκετονης για χρηση ως αναστολεις ακετyλ-coa καρβοξυλασης
CY1119530T1 (el) Συνθεσεις και μεθοδοι ρυθμισης toy fxr
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1123702T1 (el) Πυραζολο[1,5-αλφα]πυριμιδινες χρησιμες ως αναστολεις της κινασης atr για την αντιμετωπιση καρκινικων νοσων
CY1119123T1 (el) Δις-αρυλοσυζευγμενες αρυλοτριαζολονες και η χρηση τους
CY1124446T1 (el) Μορφες δοσολογιας της ρουξολιτινιμπης παρατεταμενης αποδεσμευσης
CY1123569T1 (el) Παραγωγα ισοϊνδολινο-1-ονης ως δραστικοτητα θετικου αλλοστερiκου τροποποιητη χολινεργικου μουσκαρινικου μ1 υποδοχεα για τη θεραπεια της νοσου toy alzheimer
CY1118156T1 (el) Ενωσεις αντιστροφης αμιδης ως αναστολεις δεακετυλασης πρωτεϊνων και μεθοδοι χρησης αυτων
CR20120190A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
CY1116315T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
CY1117719T1 (el) Παραγωγα αμινοπυριμιδινης ως διαμορφωτες της lrrk2
CY1117424T1 (el) Βενζοδιαζεπινικος αναστολεας bromodomain
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
UY36056A (es) “compuestos de heteroarilo o arilo bicíclicos fusionados “.
CY1116057T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
CY1116168T1 (el) Συγκρυσταλλοι και αλατα αναστολεων toy ccr3
CY1116450T1 (el) Παρασιτοκτονες ενωσεις διυδροϊσοξαζολιου
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
CY1116452T1 (el) Θετικοι αλλοστερικοι ρυθμιστες μ1 υποδοχεα του τυπου πυρανυλ αρυλ μεθυλ βενζοκιναζολινονης
CY1123216T1 (el) Αναστολεις της gls1 για την αντιμετωπιση νοσων
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
CY1117914T1 (el) Νεες μορφες και αλατα ενος αναστολεα διυδροπυρρολο[1,2-c]ιμιδαζολυλ συνθασης αλδοστερονης ή αρωματασης
CY1115729T1 (el) Τρικυκλικη ενωση και φαρμακευτικη χρηση αυτης